ESMO Presentation

Harvett has contended that the results for NOX66 plus Carboplatin presented today are similar to those achieved many years ago with Phenoxodiol delivered intravenously. He is wrong.

What he has missed, in his zeal to disparage Noxopharm, is that Carboplatin was administered at NON-TOXIC levels (AUC=4) which on its own would have absolutely no effect.

The addition of NOX66 at 800mg had two significant effects: (1) it stopped disease progression in nearly every patient, without side effects; and (2) it provided proof that 800mg would be the best dose of NOX66 to use in radiotherapy trials.

Ask yourself this: if you had terminal cancer that had failed all treatment and had weeks to live, would you want to be treated with a toxic dose of chemo that had stopped working, or would you prefer to be treated with a non-toxic dose of that chemo plus NOX66 in the knowledge that your cancer would most likely stop growing?

Idronoxil delivered by suppository is VASTLY superior to intravenous Phenoxodiol. This is a great result